Announcement • Apr 18
Acrivon Therapeutics Inc Highlights Preclinical Data with Three Posters At Aacr Demonstrating Strong Acr-368 and Acr-2316 Synergies with Immune Checkpoint Inhibitors and Adc Payloads
Acrivon Therapeutics, Inc. announced preclinical data that showed powerful synergies between its two lead assets and emerging and foundational standard-of-care anti-cancer agents. Both ACR-368, a CHK1/2 inhibitor currently in a registrational-intent Phase 2b study, and ACR-2316, a WEE1/PKMYT1 inhibitor currently in a Phase 1/2 study, showed strong synergy in combination with anti-PD-L1 checkpoint inhibition. Additionally, ACR-368 synergized with a Topo 1 inhibitor, a payload commonly used in ADCs. The data will be presented at the AACR 2026 Annual Meeting being held in San Diego, CA. The posters can be found on the Acrivon website under “Posters and Presentations”. Poster Presentation Details: Title: Potent synergy between CHK1/2 inhibitor ACR-368 and the ADC payload topoisomerase 1 inhibitor: Rationale for ADC + ACR-368 combination therapy. Date and Time: Sunday, April 19, 2026; 2:00 p.m. - 5:00 p.m. PT. Session: Experimental and Molecular Therapeutics: DNA Damage and Repair 1. Poster Number: 239. Title: ACR-368 synergizes with PD-L1 blockade by coordinated activation of adaptive and innate immunity pathways to achieve robust anti-tumor efficacy. Date and Time: Monday, April 20, 2026; 9:00 a.m. - 12:00 p.m. PT. Session: Late-Breaking Research: Immunology 2. Poster Number: LB152. Title: Treatment with ACR-2316, a potential first- and best-in-class WEE1/PKMYT1 inhibitor, combined with anti-PD-L1 induces complete tumor regression with durable immune memory. Date and Time: Monday, April 20, 2026; 2:00 p.m. - 5:00 p.m. PT. Session: Clinical Research: Combination Immunotherapies. Poster Number: 3789. Potent preclinical efficacy with durable immune memory observed in combinations of either ACR-368 or ACR-2316 with anti-PD-L1 and strong synergy of ACR-368 with Topoisomerase 1 (Topo 1) inhibition. Data supports potential for frontline clinical combinations of ACR-368 and ACR-2316 with immune checkpoint inhibitors and of ACR-368 with Topo 1 antibody-drug conjugates (ADCs). Acrivon is currently advancing its lead program, ACR-368 (also known as prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial for endometrial cancer. The company has received Fast Track designation from the Food and Drug Administration, or FDA, for the investigation of ACR-368 as a monotherapy based on OncoSignature-predicted sensitivity in patients with endometrial cancer. The FDA has granted a Breakthrough Device designation for the ACR-368 OncoSignature assay for the identification of patients with endometrial cancer who may benefit from ACR-368 treatment. In addition to ACR-368, Acrivon is also leveraging its proprietary Generative Phosphoproteomics AP3 platform for developing its co-crystallography-driven, internally discovered pipeline programs. These include ACR-2316, the company’s second clinical stage asset, a novel, potent, selective WEE1/PKMYT1 inhibitor designed for superior single-agent activity through strong activation of not only CDK1 and CDK2, but also of PLK1 to drive pro-apoptotic cell death, as observed in preclinical studies against benchmark inhibitors. The Phase 1/2 trial of ACR-2316 is advancing, with weekly dosing regimens established. Initial data has shown a favorable tolerability profile limited to transient, mechanism-based hematological adverse events, predominantly neutropenia and initial clinical activity across AP3-selected solid tumor types, including PRs in endometrial cancer, as well as SCLC and sqNSCLC, two tumor types which have not shown sensitivity to other clinical WEE1 or PKMYT1 inhibitors currently in development. In addition, the company is advancing ACR-6840 and other potential development candidates targeting CDK11.
